摘要
目的观察应用匹多莫德口服液治疗支原体肺炎的临床效果。方法 200例支原体肺炎患儿,随机分成对照组和观察组,各100例。对照组给予阿奇霉素进行治疗,观察组在对照组基础上给予匹多莫德口服液进行治疗,观察与比较两组患儿的临床疗效。结果治疗后,观察组患儿肺部啰音消失时间为(95±14)h,肺部炎症吸收时间为(78±20)h;对照组患儿肺部啰音消失时间为(167±17)h,肺部炎症吸收时间为(163±23)h;观察组肺部啰音消失时间及炎症吸收时间明显短于对照组,差异有统计学意义(P<0.05)。观察组患儿中78例痊愈、17例好转,5例无效,总有效率为95%;对照组患儿中60例痊愈、18例好转,22例无效,总有效率为78%;观察组总有效率高于对照组,差异有统计学意义(P<0.05)。治疗后,观察组患儿血清免疫球蛋白A(Ig A)和免疫球蛋白G(Ig G)以及免疫球蛋白M(Ig M)水平分别为(5.92±1.41)、(9.97±1.57)、(4.71±1.07)g/L,对照组患儿血清Ig A和Ig G以及Ig M水平分别为(4.26±1.42)、(7.81±1.44)、(3.53±1.33)g/L;观察组患儿Ig A和Ig G以及Ig M水平均高于对照组,差异有统计学意义(P<0.05)。结论针对支原体肺炎患儿予以匹多莫德口服液治疗,获取了显著的临床疗效,可以有效提升患儿的抵抗力,对临床症状具有显著的改善作用,因此可在临床上进行广泛的推广。
Objective To observe the clinical effect of pidotimod oral solution in the treatment of mycoplasma pneumonia. Methods A total of 200 mycoplasma pneumonia children were randomly divided into control group and observation group, with 100 cases in each group. The control group received azithromycin for treatment, and the observation group received pidotimod oral solution on the basis of the control group for treatment. Clinical effect was observed and compared in two groups. Results After treatment, the observation group had lung rale disappearing time as (95±14) h, lung inflammation absorption time as (78±20) h, while the control group had lung rale disappearing time as (167±17) h, lung inflammation absorption time as (163±23) h.The observation group had shorter lung rale disappearing time and inflammation absorption time than the control group, and the difference had statistical significance (P<0.05). The observation group had 78 cured cases, 17 effective cases and 5 ineffective cases, with total effective rate as 95%, while the control group had 60 cured cases,18 effective cases and 22 ineffective cases, with total effective rate as 78%. The observation group had higher total effective rate than the control group, and the difference had statistical significance (P<0.05). After treatment, the observation group had serum immunoglobulin A (IgA), immunoglobulin G (IgG) and immunoglobulin M (IgM) level respectively as (5.92±1.41), (9.97±1.57) and (4.71±1.07) g/L, while the control group had serum IgA, IgG and IgM level respectively as (4.26±1.42), (7.81±1.44) and (3.53±1.33) g/L. The observation group had higher IgA,IgG and IgM level than the control group, and the difference had statistical significance (P<0.05). Conclusion Pidotimod oral solution shows significant clinical curative effect in the treatment of mycoplasma pneumonia children. It also can effectively increase patients’ resistance and significantly improve their clinical symptoms. So it can be widely promoted in clinic.
作者
赵秀芝
ZHAO Xiu-zhi(Department of Pharmacy, Liaoning Province Fushun City Central Hospital, Fushun 113006, China)
出处
《中国现代药物应用》
2017年第5期89-91,共3页
Chinese Journal of Modern Drug Application
关键词
匹多莫德
支原体肺炎
阿奇霉素
疗效观察
Pidotimod
Mycoplasma pneumonia
Azithromycin
Curative effect observation
